Form 4: AtriCure CFO Angela Wirick Reports Stock Transactions

AtriCure's Chief Financial Officer, Angela Wirick, reports acquisition and disposal of company stock related to restricted stock and performance share awards.

Summary

• Angela Wirick, CFO of AtriCure, Inc., filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On March 1, 2025, Wirick acquired 30,330 shares of common stock through a Restricted Stock Award under the 2023 Stock Incentive Plan.
• These shares vest annually over three years from the grant date.
• On the same date, she also acquired 9,003 shares through the vesting of a Performance Share Award under the same plan, as performance goals and service requirements were met.
• Wirick disposed of 13,633 shares to satisfy tax withholding obligations related to the vesting of the Restricted Stock and Performance Share Awards at a price of $38.74 per share.
• Following these transactions, Wirick beneficially owns 164,770 shares of AtriCure common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine stock transactions related to compensation plans. The vesting of performance shares is a slightly positive signal, while the tax-related disposal is neutral.

Positives

• The vesting of performance share awards indicates that the company has met certain performance goals.
• The acquisition of shares through restricted stock awards aligns the CFO's interests with those of the shareholders.

Negatives

• The disposal of shares to cover tax obligations, while common, slightly reduces the CFO's stake in the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the medical device industry to attract and retain talent.
• Companies like Medtronic and Boston Scientific also utilize restricted stock and performance share awards as part of their executive compensation packages.
• The vesting schedules and performance metrics associated with these awards are typically aligned with long-term shareholder value creation.

Stakeholder Impact

• The transactions have a minor impact on shareholders, as they reflect standard executive compensation practices.
• Employees may be motivated by the vesting of performance shares, indicating the achievement of company goals.

Key Dates